Markets:

Overview

News

Currencies

International

Treasuries

Penumbra, Inc. Common Stock (NY:PEN)

308.75 -2.16 (-0.70%)

Streaming Delayed Price Updated: 10:05 AM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Penumbra, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Merit Medical Systems (MMSI) Q4 Earnings Report Preview: What To Look For

February 24, 2025

Medical device company Merit Medical Systems (NASDAQ:MMSI) will be announcing earnings results tomorrow after market close. Here’s what to look for.

Via StockStory

Artivion (AORT) Q4 Earnings: What To Expect

February 23, 2025

Medical device company Artivion (NYSE:AORT) will be reporting results tomorrow after the bell. Here’s what you need to know.

Via StockStory

Stroke Device Maker Penumbra Stock Surges On Earnings Beat, Analysts Boost Price Forecasts After Upbeat 2025 Outlook ↗

February 19, 2025

Penumbra stock climbs after Q4 earnings surpass expectations, with sales up 10.8% Y/Y. Analysts raise price targets as the company projects strong 2025 growth.

Via Benzinga

Topics Earnings

Why Penumbra (PEN) Stock Is Trading Up Today

February 19, 2025

Shares of medical device company Penumbra (NYSE:PEN) jumped 13.6% in the afternoon session after the company reported impressive fourth-quarter 2024 results, which blew past analysts' constant currency...

Via StockStory

10 Analysts Assess Penumbra: What You Need To Know ↗

January 21, 2025

Via Benzinga

Peering Into Penumbra's Recent Short Interest ↗

January 20, 2025

Via Benzinga

(PEN) - Analyzing Penumbra's Short Interest ↗

December 24, 2024

Via Benzinga

Garmin Posts Better-Than-Expected Results, Joins SolarEdge Technologies, Compass, Appian And Other Big Stocks Moving Higher On Wednesday ↗

February 19, 2025

Via Benzinga

Profit Machine Penumbra Surges On Solid Fourth-Quarter Beat, But Guidance Lags ↗

February 19, 2025

The company easily beat fourth-quarter expectations. But there was one drawback in its report.

Via Investor's Business Daily

Penumbra’s (NYSE:PEN) Q4 Sales Beat Estimates

February 18, 2025

Medical device company Penumbra (NYSE:PEN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 10.8% year on year to $315.5 million. On the other hand, the company’s...

Via StockStory

Topics Earnings

Penumbra (PEN) Reports Q4: Everything You Need To Know Ahead Of Earnings

February 17, 2025

Medical device company Penumbra (NYSE:PEN) will be reporting earnings tomorrow afternoon. Here’s what you need to know.

Via StockStory

Price Over Earnings Overview: Penumbra ↗

December 11, 2024

Via Benzinga

12 Analysts Assess Penumbra: What You Need To Know ↗

December 11, 2024

Via Benzinga

(PEN) - Analyzing Penumbra's Short Interest ↗

November 29, 2024

Via Benzinga

Earnings Scheduled For February 18, 2025 ↗

February 18, 2025

Via Benzinga

Breaking Down Penumbra: 11 Analysts Share Their Views ↗

November 20, 2024

Via Benzinga

How Is The Market Feeling About Penumbra? ↗

November 06, 2024

Via Benzinga

Artivion (NYSE:AORT) Q3 Earnings: Leading The Medical Devices & Supplies - Cardiology, Neurology, Vascular Pack

February 14, 2025

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the medical devices & supplies - cardiology, neurology, vascular stocks, including Artivion (NYSE:AORT) and its peers.

Via StockStory

Unpacking Q3 Earnings: ICU Medical (NASDAQ:ICUI) In The Context Of Other Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks

February 14, 2025

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including...

Via StockStory

Spotting Winners: Penumbra (NYSE:PEN) And Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks In Q3

February 13, 2025

Looking back on medical devices & supplies - cardiology, neurology, vascular stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Penumbra (NYSE:PEN) and its peers.

Via StockStory

Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q3 Teardown: Merit Medical Systems (NASDAQ:MMSI) Vs The Rest

February 13, 2025

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including Merit Medical Systems...

Via StockStory

Key Takeaways From Penumbra Analyst Ratings ↗

October 25, 2024

Via Benzinga

Looking Into Penumbra's Recent Short Interest ↗

October 18, 2024

Via Benzinga

This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

January 21, 2025

Via Benzinga

Inspire Medical's Sleep Innovations Driving Big Gains ↗

January 08, 2025

Inspire Medical, which makes innovative apnea relief devices, hit a key performance benchmark as its Relative Strength Rating jumped to 81.

Via Investor's Business Daily

UniFirst, Getty Images, Shutterstock And Other Big Stocks Moving Higher On Tuesday ↗

January 07, 2025

Via Benzinga

Inari Medical Catapults 30% On Rumored Stryker Takeover ↗

January 06, 2025

Inari is best-known for its series of catheter-like devices that remove blood clots.

Via Investor's Business Daily

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 18, 2024

Via Benzinga

Penumbra Is Poised For Growth As Blood Clot Awareness Rises: Analyst ↗

December 17, 2024

Oppenheimer predicts growth for Penumbra Inc in MT market. Analyst initiates coverage with Outperform rating and $275 target price.

Via Benzinga

This Elastic Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

December 17, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.